Details

Autor(en) / Beteiligte

• Agarwal, Yash
• Milling, Lauren E
• Chang, Jason Y H
• Santollani, Luciano
• Sheen, Allison
• Lutz, Emi A
• Tabet, Anthony
• Stinson, Jordan
• Ni, Kaiyuan
• Rodrigues, Kristen A
• Moyer, Tyson J
• Melo, Mariane B
• Irvine, Darrell J
• Wittrup, K Dane

Titel

Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity

Ist Teil von

• Nature biomedical engineering, 2022-02, Vol.6 (2), p.129-143

Ort / Verlag

England

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Anti-tumour inflammatory cytokines are highly toxic when administered systemically. Here, in multiple syngeneic mouse models, we show that the intratumoural injection of recombinantly expressed cytokines bound tightly to the common vaccine adjuvant aluminium hydroxide (alum) (via ligand exchange between hydroxyls on the surface of alum and phosphoserine residues tagged to the cytokine by an alum-binding peptide) leads to weeks-long retention of the cytokines in the tumours, with minimal side effects. Specifically, a single dose of alum-tethered interleukin-12 induced substantial interferon-γ-mediated T-cell and natural-killer-cell activities in murine melanoma tumours, increased tumour antigen accumulation in draining lymph nodes and elicited robust tumour-specific T-cell priming. Moreover, intratumoural injection of alum-anchored cytokines enhanced responses to checkpoint blockade, promoting cures in distinct poorly immunogenic syngeneic tumour models and eliciting control over metastases and distant untreated lesions. Intratumoural treatment with alum-anchored cytokines represents a safer and tumour-agnostic strategy to improving local and systemic anticancer immunity.